-
★
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
(Hinzugefügt: 15.09.2021 um 15:14 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00331-3/fulltext
-
Therapiekritik BARICITINIB (OLUMIANT) GEGEN COVID-19
(Hinzugefügt: 28.12.2022 um 14:40 Uhr)
https://www.arznei-telegramm.de/html/2022_08/2208059_01.html
-
Baricitinib versus tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: A prospective, investigational, real-world study
(Hinzugefügt: 18.11.2022 um 15:58 Uhr)
https://www.ijidonline.com/article/S1201-9712(22)00577-X/fulltext
-
BARICITINIB (OLUMIANT) GEGEN COVID-19
(Hinzugefügt: 10.11.2022 um 13:45 Uhr)
https://www.arznei-telegramm.de/html/2022_08/2208059_01.html
-
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
(Hinzugefügt: 30.10.2022 um 09:21 Uhr)
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00529-8/fulltext?dgcid=raven_jbs_aip_email
-
Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
(Hinzugefügt: 08.06.2022 um 10:01 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00219-X/fulltext
-
BARICITINIB ATTENUATES THE PROINFLAMMATORY PHASE OF COVID-19 DRIVEN BY LUNG-INFILTRATING MONOCYTES
(Hinzugefügt: 27.05.2022 um 08:15 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(22)00727-6
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
(Hinzugefügt: 27.05.2022 um 08:04 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00088-1/fulltext
-
Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2
(Hinzugefügt: 09.05.2022 um 08:51 Uhr)
https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac219/6575051
-
New RECOVERY trial result: baricitinib reduces deaths in patients hospitalised with COVID-19
(Hinzugefügt: 06.03.2022 um 18:35 Uhr)
https://www.recoverytrial.net/news/baricitinib
-
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
(Hinzugefügt: 14.02.2022 um 16:41 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00006-6/fulltext
-
WHO Recommends 2 New Drugs to Treat Patients With COVID-19
(Hinzugefügt: 24.01.2022 um 19:38 Uhr)
https://www.pharmacytimes.com/view/who-recommends-2-new-drugs-to-treat-patients-with-covid-19
-
Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
(Hinzugefügt: 21.12.2021 um 12:46 Uhr)
https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/
-
Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled Trial
(Hinzugefügt: 18.10.2021 um 10:25 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.11.21263897v1
-
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
(Hinzugefügt: 15.09.2021 um 15:02 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00358-1/fulltext
-
Baricitinib senkt COVID-19-Sterberisiko in Phase-3-Studie
(Hinzugefügt: 15.09.2021 um 14:45 Uhr)
https://www.aerzteblatt.de/nachrichten/126945/Baricitinib-senkt-COVID-19-Sterberisiko-in-Phase-3-Studie
-
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
(Hinzugefügt: 08.04.2021 um 17:12 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lilly-and-incyte-announce-results-phase-3-cov-barrier-study
-
Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
(Hinzugefügt: 02.02.2021 um 19:53 Uhr)
https://www.recoverytrial.net/news/baricitinib-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
(Hinzugefügt: 21.12.2020 um 10:57 Uhr)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031994?articleTools=true
-
COVID-19: Wann Baricitinib die Erholung bei schweren Erkrankungen beschleunigen kann
(Hinzugefügt: 15.12.2020 um 09:43 Uhr)
https://www.aerzteblatt.de/nachrichten/119305/COVID-19-Wann-Baricitinib-die-Erholung-bei-schweren-Erkrankungen-beschleunigen-kann
-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
(Hinzugefügt: 12.12.2020 um 09:00 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2031994
-
Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19
(Hinzugefügt: 29.11.2020 um 13:13 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
-
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
(Hinzugefügt: 23.11.2020 um 15:18 Uhr)
https://investor.lilly.com/news-releases/news-release-details/baricitinib-receives-emergency-use-authorization-fda-treatment
-
FDA genehmigt Notfalleinsatz von Baricitinib
(Hinzugefügt: 23.11.2020 um 15:18 Uhr)
https://www.aerzteblatt.de/nachrichten/118582/COVID-19-FDA-genehmigt-Notfalleinsatz-von-Baricitinib